Bayer invest 500 million Euros to expand its capacity

With an investment of more than 500 million Euros at its sites in Wuppertal and Leverkusen, Germany, Bayer will establish additional capacities for the manufacturing of the recombinant factor VIII (rFVIII) hemophilia products that are currently in development .


The investigational therapy options for hemophilia patients - a plasma protein-free rFVIII (BAY 81-8973) and a long-acting rFVIII (BAY 94-9027) - are both currently in Phase III clinical trials.

In February 2014, Bayer HealthCare announced positive results from the PROTECT VIII trial evaluating Bayer's site-specific PEGylated rFVIII (BAY 94-9027).

"This investment will be one of the largest in the history of Bayer HealthCare and reflects our strong commitment in the field of hemophilia A," said Dr Olivier Brandicourt, ceo, Bayer HealthCare.

Bayer's approved hemophilia A therapy product Kogenate FS/Kogenate Bayer is manufactured exclusively in Berkeley, California, USA.

Establishing an additional supply source in Germany will help the company to prepare for production of the anticipated new therapy options and address the growing demand in this therapeutic area.


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email